Objective: To analyse the changes and clinical implication of biomarkers in exhaled breath condensates (EBC) of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) before and after treatment. Methods: 20 patients with AECOPD were enrolled, including 15 males and 5 females. The average age was 71±10, ranging from 50-85. The concentrations of Leukotriene B4 (LTB4) and Interleukin 6 (IL-6) from EBC were assayed by ELISA kit before and after treatment. Serum inflammatory indexes, pulmonary function test and quality of life (CAT) were observed at the same time, the relationship between EBC biomarkers and clinical markers were investigated. Results: The concentration of LTB4 and IL-6 of AECOPD patients with treated [(20.79±2.27)ng/L, (0.39±0.18)ng/L, respectively], were significantly lower compared with that before treatment [(22.64±3.01)ng/L, (0.60±0.36)ng/L, P<0.05, respectively]. The percentage of neutrophils, CRP were decreased after treatment. But no correlation was found between LTB4, IL-6 and serum inflammatory indexes, pulmonary function or CAT(P>0.05). Conclusion: The concentration of biomarkers (LTB4, IL-6) in EBC of AECOPD patients can dynamically monitor the inflammation in respiratory tract and evaluate the therapeutic effect.
目的：分析慢性阻塞性肺疾病(慢阻肺)急性加重患者治疗前后呼出气冷凝液(EBC)中白细胞介素-6与白三烯B4的变化及临床意义。 方法：前瞻性纳入慢阻肺急性加重患者20例，其中男15例，女5例，年龄50～85岁，平均(71±10)岁，采用酶联免疫分析法检测患者治疗前后EBC中白三烯B4和IL-6水平，并常规检测C反应蛋白、肺功能及生活质量评分(CAT)，分析比较EBC中白三烯B4和IL-6与其他临床指标的相关性。 结果：慢阻肺急性加重患者治疗后EBC中白三烯B4和IL-6水平[(20.79±2.27) ng/L、(0.39±0.18) ng/L]较治疗前[(22.64±3.01) ng/L、(0.60±0.36) ng/L]降低，差异有统计学意义(P<0.05)。患者血清中性粒细胞比例和C反应蛋白治疗后也有所降低，但白三烯B4和IL-6水平与肺功能、中性粒细胞比例、C反应蛋白及CAT均无明显相关性(P>0.05)。 结论：慢阻肺急性加重患者或可采用EBC生物标志物白三烯B4和IL-6动态检测呼吸道炎症水平及评价治疗效果。.
Keywords: Exhaled breath condensate; Pulmonary disease, chronic obstructive; Pulmonary function test.